May 28, 2025 - 00:25

Chad Rigetti has announced the launch of his new startup, Sygaldry, which aims to revolutionize the intersection of quantum computing and artificial intelligence. Rigetti believes that Sygaldry will differentiate itself from existing competitors in the quantum space, as many of these companies developed their business strategies long before the recent surge in AI adoption.
In a discussion with Caroline Hyde and Ed Ludlow on a technology-focused platform, Rigetti emphasized the unique position of Sygaldry in a rapidly evolving market. He expressed confidence that the startup's fresh approach and innovative technology will allow it to capitalize on the growing demand for advanced AI solutions powered by quantum computing.
As industries increasingly seek to harness the power of AI, Rigetti's vision for Sygaldry positions the company to play a pivotal role in shaping the future of both quantum technology and artificial intelligence. The startup, backed by Y Combinator, is set to make waves in the tech world as it embarks on this ambitious journey.
March 2, 2026 - 07:46
Canon: "New Technology" Compact Model is ComingPhotography enthusiasts and industry watchers are abuzz as Canon has released tantalizing hints about a new compact camera model currently in development. While full specifications and an official...
March 1, 2026 - 18:53
Digital Frontiers Reshape Montana's LandscapeThe spirit of innovation that once rode the rails into Montana is finding new expression in the digital age. Across the state, from sprawling ranches to remote mountain towns, modern technology is...
March 1, 2026 - 04:37
Silicon Valley Rallies Behind Anthropic in A.I. Clash With TrumpA significant rift appears to be widening between the federal government and the American technology sector, as industry leaders and workers rally behind artificial intelligence startup Anthropic....
February 28, 2026 - 04:58
Rare Disease Day: Revolutionising clinical trial enrolment and retention with technologyOn Rare Disease Day, the focus sharpens on the unique challenges of developing treatments for conditions affecting small, often geographically dispersed patient populations. A key industry expert...